Alterity Therapeutics Ltd (ATHE)

$1.24

-0.02

(-1.59%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $1.23
    $1.34
    $1.24
    downward going graph

    0.81%

    Downside

    Day's Volatility :8.21%

    Upside

    7.46%

    downward going graph
  • $1.01
    $5.41
    $1.24
    downward going graph

    18.55%

    Downside

    52 Weeks Volatility :81.33%

    Upside

    77.08%

    downward going graph

Returns

PeriodAlterity Therapeutics LtdIndex (Russel 2000)
3 Months
-32.98%
0.0%
6 Months
-25.3%
0.0%
1 Year
-54.83%
0.0%
3 Years
-90.81%
-22.3%

Highlights

Market Capitalization
11.0M
Book Value
$0.0
Earnings Per Share (EPS)
-2.1
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-716.34%
Return On Assets TTM
-53.38%
Return On Equity TTM
-104.47%
Revenue TTM
3.8M
Revenue Per Share TTM
0.6
Quarterly Revenue Growth YOY
20.9%
Gross Profit TTM
3.6M
EBITDA
-19.8M
Diluted Eps TTM
-2.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.21
EPS Estimate Next Year
-0.09
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Analyst Forecast

What analysts predicted

Upside of 464.52%

Current $1.24
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
150.7K
↑ 51.95%
Net Income
-6.2M
↑ 9.59%
Net Profit Margin
-4.1K%
↑ 1587.85%
FY19Y/Y Change
Revenue
75.4K
↓ 46.05%
Net Income
-8.6M
↑ 49.26%
Net Profit Margin
-11.4K%
↓ 7258.54%
FY20Y/Y Change
Revenue
283.9K
↑ 279.19%
Net Income
-6.9M
↓ 18.46%
Net Profit Margin
-2.4K%
↑ 8923.05%
FY21Y/Y Change
Revenue
2.5M
↑ 690.65%
Net Income
-11.7M
↑ 52.19%
Net Profit Margin
-470.47%
↑ 1973.77%
FY22Y/Y Change
Revenue
2.5M
↑ 8.71%
Net Income
-9.0M
↓ 16.08%
Net Profit Margin
-363.18%
↑ 107.29%
FY23Y/Y Change
Revenue
1.8M
↓ 26.26%
Net Income
-9.3M
↑ 7.47%
Net Profit Margin
-529.3%
↓ 166.12%
Q1 FY22Q/Q Change
Revenue
762.5K
↑ 20.68%
Net Income
-1.7M
↓ 2.01%
Net Profit Margin
-226.58%
↑ 52.48%
Q2 FY22Q/Q Change
Revenue
536.3K
↓ 26.23%
Net Income
-1.8M
↑ 9.6%
Net Profit Margin
-336.65%
↓ 110.07%
Q3 FY22Q/Q Change
Revenue
511.0K
↑ 0.0%
Net Income
-1.7M
↑ 0.0%
Net Profit Margin
-336.65%
↑ 0.0%
Q4 FY22Q/Q Change
Revenue
548.1K
↑ 6.44%
Net Income
-1.8M
↑ 6.44%
Net Profit Margin
-336.65%
↑ 0.0%
FY18Y/Y Change
Total Assets
14.0M
↓ 25.93%
Total Liabilities
2.0M
↑ 66.25%
FY19Y/Y Change
Total Assets
13.8M
↑ 6.32%
Total Liabilities
2.3M
↑ 26.86%
FY20Y/Y Change
Total Assets
9.2M
↓ 33.17%
Total Liabilities
1.9M
↓ 17.83%
FY21Y/Y Change
Total Assets
25.6M
↑ 152.43%
Total Liabilities
2.4M
↑ 13.0%
FY22Y/Y Change
Total Assets
29.1M
↑ 23.16%
Total Liabilities
4.1M
↑ 89.2%
FY23Y/Y Change
Total Assets
18.4M
↓ 33.96%
Total Liabilities
3.0M
↓ 23.57%
Q1 FY22Q/Q Change
Total Assets
33.1M
↑ 0.0%
Total Liabilities
3.2M
↑ 14.56%
Q2 FY22Q/Q Change
Total Assets
15.0M
↓ 52.48%
Total Liabilities
2.4M
↓ 23.17%
Q3 FY22Q/Q Change
Total Assets
14.3M
↑ 0.0%
Total Liabilities
2.2M
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
22.5M
↑ 56.35%
Total Liabilities
3.6M
↑ 57.77%
Q2 FY23Q/Q Change
Total Assets
18.4M
↓ 18.17%
Total Liabilities
3.0M
-
FY18Y/Y Change
Operating Cash Flow
-4.7M
↑ 6.48%
Investing Cash Flow
-13.8K
↓ 34.03%
Financing Cash Flow
-80.7K
↓ 32.52%
FY19Y/Y Change
Operating Cash Flow
-9.7M
↑ 123.45%
Investing Cash Flow
-4.9K
↓ 61.87%
Financing Cash Flow
8.8M
↓ 11915.14%
FY20Y/Y Change
Operating Cash Flow
-6.5M
↓ 32.42%
Investing Cash Flow
-11.5K
↑ 138.45%
Financing Cash Flow
2.7M
↓ 68.7%
FY21Y/Y Change
Operating Cash Flow
-13.2M
↑ 83.75%
Investing Cash Flow
-8.0K
↓ 37.46%
Financing Cash Flow
28.1M
↑ 823.89%
FY22Y/Y Change
Operating Cash Flow
-8.7M
↓ 28.81%
Investing Cash Flow
-62.7K
↑ 751.29%
Financing Cash Flow
11.6M
↓ 54.98%
FY23Y/Y Change
Operating Cash Flow
-13.5M
↑ 62.64%
Investing Cash Flow
-24.5K
↓ 59.1%
Financing Cash Flow
119.6K
↓ 98.93%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.6M
↑ 15.56%
Investing Cash Flow
-10.5K
↑ 547.48%
Financing Cash Flow
83.5K
↓ 214.79%
Q2 FY23Q/Q Change
Operating Cash Flow
368.8K
↓ 114.06%
Investing Cash Flow
-10.6K
↑ 0.0%
Financing Cash Flow
-11.4K
↓ 113.6%

Technicals Summary

Sell

Neutral

Buy

Alterity Therapeutics Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alterity Therapeutics Ltd
Alterity Therapeutics Ltd
-4.62%
-25.3%
-54.83%
-90.81%
-88.35%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alterity Therapeutics Ltd
Alterity Therapeutics Ltd
NA
NA
NA
-1.21
-1.04
-0.53
NA
0.0
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alterity Therapeutics Ltd
Alterity Therapeutics Ltd
NA
$11.0M
-88.35%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Alterity Therapeutics Ltd

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 762.98K → 812.11K (in $), with an average increase of 6.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -2.34M → -2.73M (in $), with an average decrease of 5.4% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 91.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 160.0%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    0.59%

  • XTX Topco Ltd

    0.20%

  • Twin Lakes Capital Management, LLC

    0.07%

Company Information

alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.

Organization
Alterity Therapeutics Ltd
Employees
11
CEO
Mr. Geoffrey Paul Kempler B.Sc.
Industry
Biotechnology

Discover More

FAQs